Drawing for EPIPHIA

USPTO serial 98049184

EPIPHIA

Reviewed by CopyMark Law Group

Status 733Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
MOSCATI, JUSTIN RONALD
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 733: Status 733 means the fourth six-month extension was granted. Only one extension typically remains before you must file a Statement of Use or risk abandonment.

Need help with EPIPHIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*

Plus Government fees of $600

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anthony R Barkume

Anthony R Barkume SUTTON MAGIDOFF BARKUME LLP315 MADISON AVE3RD FLOORNEW YORK, NY 10017

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer software using artificial intelligence for analyzing volatile organic compounds for disease detection; Downloadable computer programs using artificial intelligence for analyzing volatile organic compounds for disease detection; Recorded computer software using artificial intelligence for analyzing volatile organic compounds for disease detection; Recorded computer programs using artificial intelligence for analyzing volatile organic compounds for disease detectionACTIVE—
010Diagnostic apparatus for the detection of cancer; Medical diagnostic apparatus for testing DNA and RNA samples; Medical diagnostic apparatus for detecting cancer; Medical diagnostic apparatus for testing volatile organic compounds relating to cancer, virus, pathogenic entities, metabolic diseases, autoimmune diseases; Medical diagnostic apparatus for testing volatile organic compounds relating to cancer, virus, pathogenic entities, metabolic diseases, autoimmune diseases incorporating recorded operating system software; Medical diagnostic apparatus for testing volatile organic compounds relating to cancer, virus, pathogenic entities, metabolic diseases, autoimmune diseases incorporating recorded software for comparing a sample's data set to a library of datasets associated with a diseaseACTIVE—
042Providing temporary use of on-line non-downloadable software and applications using artificial intelligence for analyzing volatile organic compounds for disease detection; Providing temporary use of on-line non-downloadable cloud computing software using artificial intelligence for analyzing volatile organic compounds for disease detectionACTIVE—
044Medical testing for diagnostic or treatment purposes in the field of analyzing volatile organic compounds for disease detection; Providing information concerning the use of medical diagnostic imaging equipment by means of a web site; Virus testing for medical diagnostic or treatment purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 10, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 9, 2026EX4GSOU EXTENSION 4 GRANTED—
Jun 9, 2026EXT4SOU EXTENSION 4 FILED—
Jun 9, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 8, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 8, 2025EX3GSOU EXTENSION 3 GRANTED—
Dec 8, 2025EXT3SOU EXTENSION 3 FILED—
Dec 8, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 15, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 2, 2025EX2GSOU EXTENSION 2 GRANTED—
Jun 2, 2025EXT2SOU EXTENSION 2 FILED—
Jun 2, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 3, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 3, 2024EX1GSOU EXTENSION 1 GRANTED—
Dec 3, 2024EXT1SOU EXTENSION 1 FILED—
Dec 3, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 11, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 16, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 16, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 27, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 8, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 7, 2024DOCKASSIGNED TO EXAMINER—
Jul 22, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 22, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance